Featured
-
Postponement of MMM 2020
2020-04-01
It is with reluctance and sadness that, due to the global impact of the COVID-19 pandemic, the May Measurement Month (MMM) Global Project Team has made the decision that MMM20 should not take place this year.
We hope that volunteers will understand and support this decision. We look forward to planning MMM21 together.
-
Joint Meeting ESH-ISH 2020 - NEW DATES
2020-03-23
Dear Colleagues,
The organizing committee of the 2020 ESH-ISH Joint Meeting in Glasgow, would like to inform you that in view of the global unprecedented situation related to COVID-19, the ESH-ISH Joint Meeting, has been rescheduled to April 11-14, 2021.
-
A statement from the International Society of Hypertension on COVID-19
2020-03-16
The International Society of Hypertension (ISH) is aware of concern raised by speculation, which was amplified by the media and which suggested that hypertension (raised blood pressure) increases susceptibility to infection with COVID-19. Further speculation reportedly suggested that two commonly used classes of blood pressure lowering agents (ACE-Inhibitors and Angiotensin Receptor Blockers (ARBs)) may worsen the outcome for those who are infected with COVID-19 (1).
The ISH completely endorses the content of two recent statements made by the Council on Hypertension of the European Society of Cardiology and the European Society of Hypertension (2,3) both of which made clear that there is no good evidence to change the use of ACE-inhibitors or ARBs for the management of raised blood pressure in the context of avoiding or treating COVID-19 infection.
-
ISH Hypertension News
2020-03-13
We are delighted to share with you the March 2020 issue of ISH Hypertension News.
ISH Hypertension News is available online @ http://ish-world.com/news/a/hypertensionnews/, ISSN: 2520-2782
-
ISH Awards Announced
2020-02-24
New Awards Supported by the ISH Mentoring and Training Committee and the ISH Women in Hypertension Research Committee Announced.
-
Fundamentals for Implementing a Hypertension Program in Resource-Constrained Settings
2020-02-24
ISH-supported Online Course aims to help program managers and implementers in designing, planning, and implementing a hypertension control program.
-
ISH Partners in Omron Online Academy Hypertension Course
2019-10-18
The ISH is pleased to support our educational partner Omron Heathcare in the launch of a new online curriculum on hypertension.
-
2020 ISH/ESH Scientific Meeting
2019-10-16
The Joint Meeting of the European Society of Hypertension (ESH) and International Society of Hypertension (ISH) will be held in Glasgow, UK, from May 30 to June 1, 2020.
-
STRIDE BP: ISH Supported initiative for accurate blood pressure measurement
2019-07-11
STRIDE BP provides lists of accurate devices for office, home and ambulatory…
-
Professor Maciej Tomaszewski named ISH President - Elect
2019-06-13
The ISH is pleased to announce that Professor Maciej Tomaszewski is the President-Elect of the Society. He will take up the Presidential office at the conclusion of the ISH/ESH 2020 meeting in Glasgow
You are viewing articles tagged with "During 12/2015".
-
Can we translate the results of SPRINT into clinical practice?
The much awaited results of the Systolic Blood Pressure Intervention Trial (SPRINT) have recently been published.
Read More 15/12/2015
-
Renew your ISH 2016 membership
Receive your annual subscription to the Journal of Hypertension, substantial savings on registration fees for the ISH Biennial Scientific Meetings and much more.
Read More 10/12/2015
-
An interview with Amit Tirosh - ISH December new investigator of the month
Amit is a Senior Endocrinologist at Rabin Medical Center, Israel. Visiting attending endocrinologist, National Institutes of Health. He is interested in the diagnosis of hypercortisolism, and in the prevention of its deleterious effects, including hypertension, hyperglycemia and hypercoagulability.
Read More 02/12/2015
-
Sex, drugs and trials galore
We are delighted to present you with the December 2015 issue of ISH Hypertension News.
This includes coverage of the results of four trials, all of which have important implications for clinical practice in relation to improving CVD prevention. Three of these trials - SPRINT and two PATHWAYS trials - have clinical implications for hypertension management (how low to go and how to do it) and one EMPA-REG provides unique data regarding optimal glucose lowering with a new class of agents for the prevention of CVD in patients with type 2 diabetes!Read More 02/12/2015